- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Readers respond to GTech's bribery woes and Michael Belkin's bearishness. Plus, Mr. P speaks.
Sometimes foreign issues keep you from seeing the potential of stocks in your own backyard.
Analyst Michael Belkin has already been right this year. He says the real bear market is just starting.
With so much computing power wasted, harnessing the leftovers could become the next big thing.
Momentum investors hoisted REITs, then fled on rate fears. They were wrong to quit on these six.
States rely heavily on lotteries to pay for all kinds of services. Here are two firms poised to cash in.
As U.S. politics hurt U.S. products, the world's most recognized companies could suffer most.
After The Phoenix Cos. canned John LaForge, big investors followed him. Little guys weren't as lucky.
Investors are still rewarding innovation, turnarounds, takeovers and hidden virtues.
Investors' appetite for passive funds has given a lot of clout to four huge index-fund managers.